Bausch Health Companies Inc. (NYSE:BHC) Given Average Recommendation of “Hold” by Analysts

Bausch Health Companies Inc. (NYSE:BHC) has earned an average recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $7.33.

Several brokerages have recently issued reports on BHC. StockNews.com downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Tuesday. Jefferies Financial Group cut their price target on Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Royal Bank of Canada reduced their price objective on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a research report on Friday, August 2nd. Piper Sandler lowered Bausch Health Companies from a “neutral” rating to an “underweight” rating and dropped their target price for the company from $9.00 to $3.00 in a research report on Friday, August 2nd. Finally, Scotiabank reduced their price target on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a research report on Friday, August 2nd.

Insider Activity at Bausch Health Companies

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $6.21, for a total value of $83,027.70. Following the completion of the sale, the executive vice president now owns 435,198 shares in the company, valued at $2,702,579.58. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 8.12% of the company’s stock.

Institutional Investors Weigh In On Bausch Health Companies

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Bausch Health Companies by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 11,713,993 shares of the company’s stock worth $124,285,000 after buying an additional 114,862 shares during the period. Norges Bank acquired a new stake in Bausch Health Companies in the 4th quarter worth about $31,121,000. Natixis boosted its holdings in Bausch Health Companies by 14.3% in the 1st quarter. Natixis now owns 3,652,200 shares of the company’s stock valued at $38,707,000 after purchasing an additional 456,000 shares during the period. Hillsdale Investment Management Inc. grew its position in shares of Bausch Health Companies by 1,050.8% during the 1st quarter. Hillsdale Investment Management Inc. now owns 3,409,383 shares of the company’s stock worth $36,135,000 after purchasing an additional 3,113,123 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Bausch Health Companies by 12.1% during the second quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company’s stock worth $22,063,000 after purchasing an additional 341,936 shares during the period. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Trading Up 2.6 %

Shares of Bausch Health Companies stock opened at $7.18 on Friday. The stock’s fifty day simple moving average is $6.24 and its 200 day simple moving average is $7.36. The company has a market capitalization of $2.59 billion, a PE ratio of -5.79 and a beta of 0.75. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $11.46.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.09. Bausch Health Companies had a negative return on equity of 742.06% and a negative net margin of 5.12%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.33 billion. During the same quarter in the previous year, the business posted $0.81 EPS. Analysts predict that Bausch Health Companies will post 3.61 EPS for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.